This topic contains a solution. Click here to go to the answer

Author Question: A neonate receiving inhaled nitric oxide (iNO) for the treatment of persistent pulmonary ... (Read 70 times)

geoffrey

  • Hero Member
  • *****
  • Posts: 880
A neonate receiving inhaled nitric oxide (iNO) for the treatment of persistent pulmonary hypertension is receiving 80 ppm of iNO, and an Fio2 of 0.80. What should be the therapist's concern in this situation?
 
  A. that the patient will develop O2 toxicity
  B. that the patient will develop ventilator induced lung injury
  C. that the patient will develop rebound vasoconstriction
  D. that the patient will develop methemoglobinemia

Question 2

How is methemoglobinemia treated?
 
  A. infusion of methylene blue
  B. decreased doses of iNO
  C. infusion of NADH methemoglobin reductase
  D. increasing the Fio2



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

TINA

  • Sr. Member
  • ****
  • Posts: 336
Answer to Question 1

ANS: C
A. Incorrect response: See explanation C.
B. Incorrect response: See explanation C.
C. Correct response: Methemoglobin (metHb) results when the iron atom in heme is oxidized from Fe2+ (ferrous ion) to Fe3+ (ferric ion). In the ferric state (oxidized form), iron is incapable of binding with O2, and the affinity of other heme groups for O2 increases (i.e., shifts the oxyhemoglobin curve to the left). The normal methemoglobin blood level (<2) may be due in part to metabolism of endogenous NO. Methemoglobin reductase within erythrocytes converts endogenously produced methemoglobin to normal hemoglobin. Methemoglobinemia is uncommon at the NO doses used for therapeutic (20 ppm) inhalation. A few cases of methemoglobinemia have been reported in association with iNO therapy, generally with high doses of iNO (e.g., 80 or more ppm). In patients with decreased methemoglobin reductase, methemoglobinemia will be more likely.
D. Incorrect response: See explanation C.

Answer to Question 2

ANS: A
A. Correct response: The usual treatment of methemoglobinemia is infusion of methylene blue, which increases NADH methemoglobin reductase. Methemoglobinemia can also be treated with ascorbic acid (vitamin C). The production of methemoglobin in patients treated with iNO is dose-dependent; methemoglobinemia is rare at usual therapeutic doses of less than 20 ppm.
B. Incorrect response: See explanation A.
C. Incorrect response: See explanation A.
D. Incorrect response: See explanation A.





 

Did you know?

The human body's pharmacokinetics are quite varied. Our hair holds onto drugs longer than our urine, blood, or saliva. For example, alcohol can be detected in the hair for up to 90 days after it was consumed. The same is true for marijuana, cocaine, ecstasy, heroin, methamphetamine, and nicotine.

Did you know?

No drugs are available to relieve parathyroid disease. Parathyroid disease is caused by a parathyroid tumor, and it needs to be removed by surgery.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

When Gabriel Fahrenheit invented the first mercury thermometer, he called "zero degrees" the lowest temperature he was able to attain with a mixture of ice and salt. For the upper point of his scale, he used 96°, which he measured as normal human body temperature (we know it to be 98.6° today because of more accurate thermometers).

Did you know?

Hyperthyroidism leads to an increased rate of metabolism and affects about 1% of women but only 0.1% of men. For most people, this increased metabolic rate causes the thyroid gland to become enlarged (known as a goiter).

For a complete list of videos, visit our video library